Monthly Archives: September 2011

BRISBANE, Calif., Sept. 12, 2011 /PRNewswire via COMTEX/ — InterMune, Inc. (NASDAQ: ITMN) today announced that Esbriet® (pirfenidone) will be offered to patients in Germany beginning September 15, 2011. This will mark the first time Esbriet will be commercially available … Continue reading →

September 06 2011 IntelGenx to Present at the Rodman & Renshaw 13th Annual Healthcare Conference in New York http://www.marketwatch.com/story/intelgenx-to-present-at-the-rodman-renshaw-13th-annual-healthcare-conference-in-new-york-2011-09-06 Drug = INT0024 Testing Information at: http://www.intelgenx.com/_assets/pdf/Intelgenx-FactSheet.pdf 

(RTTNews) – Swiss biopharmaceutical company Actelion Ltd (ALIOF.PK: News ) on Monday said an exploratory phase II study with macitentan in patients with idiopathic pulmonary fibrosis or IPF did not meet its primary endpoint of forced vital capacity. The company … Continue reading →

GlobalData valued the global idiopathic pulmonary fibrosis (IPF) therapeutics market at $74.0m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 50.2% over the next eight years to reach $1919.9m in 2018. This high … Continue reading →

A study has found that epithelial cells derived from human amnion fluid (hAECs) are therapeutic when transplanted into laboratory mice modelling lung disease. “Respiratory disease is a leading cause of morbidity and mortality,” said corresponding author Dr. Euan M. Wallace, … Continue reading →

COCOA, Fla., Aug. 23, 2011 /PRNewswire/ — GeNO LLC, (www.genollc.com) a privately held, advanced development-stage technology company, today announced that it has received a new federal grant to help fund the development of its NITROSYL(TM) (Nitric Oxide for Inhalation) System … Continue reading →